Affluent Medical SAS Cash Flow Conversion Efficiency
Affluent Medical SAS cash flow conversion efficiency. Based on the latest financial reports, Affluent Medical SAS (AFME) has a cash flow conversion efficiency ratio of -0.319x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.74 Million ≈ $-7.88 Million USD) by net assets (€21.11 Million ≈ $24.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Affluent Medical SAS (2016–2024)
Cash flow conversion efficiency of Affluent Medical SAS from 2016 to 2024. This chart illustrates how Affluent Medical SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Affluent Medical SAS stock price today for real-time trading data and today's change.
Affluent Medical SAS Cash Flow Conversion Ratio Explained
Affluent Medical SAS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Affluent Medical SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Affluent Medical SAS ranked by their cash flow conversion efficiency. Also see Affluent Medical SAS market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GoldMoney Inc
TO:XAU
|
0.050x |
|
Solteam Electronics Co Ltd
TWO:3484
|
0.040x |
|
Edison Opto Corp
TW:3591
|
0.012x |
|
Wooree Bio Co.Ltd
KQ:082850
|
-0.053x |
|
MSM Malaysia Holdings Bhd
KLSE:5202
|
0.058x |
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
-0.145x |
|
TCM Group
CO:TCM
|
0.087x |
|
Poh Kong Holdings Bhd
KLSE:5080
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Affluent Medical SAS (2016–2024)
The table below shows the annual cash flow conversion efficiency of Affluent Medical SAS from 2016 to 2024. Review how financially flexible is Affluent Medical SAS to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €30.27 Million ≈ $35.39 Million |
€-11.32 Million ≈ $-13.24 Million |
-0.374x | +2.33% |
| 2023-12-31 | €31.47 Million ≈ $36.79 Million |
€-12.05 Million ≈ $-14.09 Million |
-0.383x | -16.94% |
| 2022-12-31 | €33.83 Million ≈ $39.55 Million |
€-11.08 Million ≈ $-12.95 Million |
-0.328x | -15.33% |
| 2021-12-31 | €43.53 Million ≈ $50.90 Million |
€-12.36 Million ≈ $-14.45 Million |
-0.284x | -12.16% |
| 2020-12-31 | €35.29 Million ≈ $41.26 Million |
€-8.94 Million ≈ $-10.45 Million |
-0.253x | +35.66% |
| 2019-12-31 | €30.96 Million ≈ $36.20 Million |
€-12.19 Million ≈ $-14.25 Million |
-0.394x | -122.87% |
| 2017-12-31 | €61.39 Million ≈ $71.78 Million |
€-10.84 Million ≈ $-12.68 Million |
-0.177x | +4.12% |
| 2016-12-31 | €58.87 Million ≈ $68.82 Million |
€-10.84 Million ≈ $-12.68 Million |
-0.184x | -- |
About Affluent Medical SAS
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more